Conclusion
Expanded the conclusion section to reconcile the findings from the current study with other work in this field. Specifically acknowledged several hypotheses associated with LXR/RXR agonism that were not addressed in this study.
Highlights include: 1. Differences in findings between labs could very well be a result of a variety of factors related to the methodologies employed 2. We recognize that LXR/RXR agonism may affect the pathology of AD in other ways (e.g. increased phagocytic clearance of amyloid deposits (Savage 2015) or may directly affect the cognitive decline via non-Abetadependent mechanisms not yet fully understood (Jack 2016)
3. Abeta42 was not measured nor was regional Abeta analysis performed in the brain 4. APP transgenic mice were not used in this study therefore amyloid plaque burden or cognitive changes previously described using these mice could not be assessed 5. Because the current study used non-transgenic rats, the impact of human APOE or APOE isoform-specific effects on LXR/RXR agonism, something others have shown to be an important variable, were beyond the scope of this study 
Introduction
Alzheimer's disease (AD) is a debilitating neurodegenerative disease and the leading cause of dementia in the elderly. It is currently estimated that 5 million people in the US and 30 million worldwide are afflicted with this disease. The pathological hallmarks of AD are the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles in the hippocampus and cortical areas of the brain 1 . The core constituent of the amyloid plaques is a 4 kDa peptide known as amyloid-β peptide (Aβ). Aggregation of Aβ into soluble, multimeric assemblies and insoluble amyloid fibrils is hypothesized to contribute directly to the pathogenesis of AD; therefore therapeutic strategies aimed at lowering soluble Aβ levels in the brain would be predicted to have a disease-modifying effect 2 .
The E4 allele of apolipoprotein E (APOE) is the largest genetic risk factor for sporadic, late-onset AD. The presence of a single copy of E4 increases the risk for Alzheimer's disease 3-fold and individuals with 2 copies are 15 times more likely to develop AD 3 . Data showing that APOE4 carriers begin to accumulate amyloid deposits earlier in life relative to non-carriers 4 has led to the hypothesis that increased risk associated with an E4 genotype may be the result of the effects of APOE on Aβ production, turnover and/or clearance from the central nervous system (CNS).
The expression of genes encoding lipid-transport proteins, including APOE is transcriptionally regulated by the ligand-activated nuclear receptors, peroxisome proliferator-activated receptor gamma (PPARγ) and liver X receptors (LXRs) which form obligate heterodimers with retinoid X receptors (RXRs)
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. Additionally, activation of these receptors has been shown to affect the activation state of macrophage and microglia 6 . Based on the processes influenced by this nuclear receptor family it is a reasonable hypothesis that agonism of one or more members of the family could have beneficial effects on Aβ homeostasis in the CNS. In addition, it was reported that a highly selective, blood-brainbarrier-permeant, RXR agonist, bexarotene (Targretin), enhanced clearance of soluble Aβ in an APP transgenic mouse model in an APOE-dependent manner. In the same study, Aβ plaque burden was reduced by more than 50% within 72 hours. Further, bexarotene treatment also resulted in a similar reduction (~25%) in brain interstitial fluid (ISF) levels of Aβ in non-transgenic, C57Bl/6 mice 7-12 hours following a single administration 13 . Attempts to replicate the bexarotene findings resulted in mixed results (see reviews by Tesseur & De Strooper 14 and Tousi 15 ). This study aims to examine the robustness of the hypothesis that RXR or LXR agonism affects soluble Aβ homeostasis in the CNS.
Materials and methods
In vivo pharmacodynamic studies: All procedures were approved by the Amgen Institutional Animal Care and Use Committee. Young male Sprague-Dawley rats (175-200 g) were purchased from Harlan (Indianapolis, IN) and were maintained on a 12h light/dark cycle with unrestricted access to food and water until use. Rats were dosed orally for 3 and 7 consecutive days with AMG8155, a proprietary small molecule BACE1 inhibitor, at 3 mg/kg in 2% HPMC and 1% Tween 80, pH 2, bexarotene (Alfa Aesar, Ward Hill, MA) at 100 mg/kg in 30% Labrasol, 1% Tween 20, 2% Providone and 0.05% BHA, pH7.0 (Vehicle 3), and T0901317, a LXR agonist (Fisher Scientific, Pittsburgh, PA), at 30 mg/kg in 0.5% NaCl, 2% Tween 80 (Vehicle 4). 4 hours post dose on the last day of study, rats were euthanized with CO 2 inhalation for 2 minutes and the cisterna magna was quickly exposed by removing the skin and muscle above it. Cerebrospinal fluid (CSF) was collected with a 30 gauge needle inserted through the dura membrane covering the cisterna magna. CSF samples with visible blood contamination were discarded. Blood was withdrawn by cardiac puncture and plasma was obtained by centrifugation at 15,000 rpm for 10 min at 4°C for drug exposure. Brains were removed and, along with the CSF, immediately frozen on dry ice and stored at -80°C until use. The frozen brains were subsequently homogenized in 10 volumes (w/v) of 0.5% Triton X-100 in TBS with protease inhibitors cocktails. The homogenates were centrifuged at 355,000 rpm for 30 min at 4°C.
Quantification of Aβ40 and APOE in brain and CSF: Samples are analyzed for Aβ levels by immunoassay with a MSD imager. Briefly, 96-well avidin plates (MesoScale Discovery, Inc., Gaithersburg, MD) were coated with biotinylated-anti-Aβ antibody 4G8 (mouse monoclonal, Cat# Sig 39240-1000, Covance Research Products, Princeton, NJ) at 10 μg/ml in PBS. Samples were co-incubated in the plate overnight at 4°C along with a rutheniumlabeled anti-Aβ antibody specific for the C-terminal region of Aβ40 (ConFab40; Amgen, Thousand Oaks, CA). Plates were then washed, 150 μl/well read buffer T (MesoScale Discovery, Inc.) was added, and plates were read immediately on a Sector 6000 imager according to the manufacturer's recommended protocol (MesoScale Discovery, Inc.). All samples were assayed in triplicate and analyzed by using Prism version 5.04 (GraphPad Software Inc., San Diego, CA). Data was analyzed by one-way analysis of variance and Dunnett's multiple comparison test.
APOE levels in brain (50 μg homogenates) and CSF (10 μl) were analyzed by Western blot following PAGE using 4-12% Bis-Tris gels (Invitrogen, Carlsbad, CA). Blots were probed with primary antibodies to APOE (goat polyclonal, EMD Millipore; 1:1000) and the loading control, actin (ThermoFisher Scientific; 1:200) for 60 min at 4°C and then washed with TBST (Tris-buffered saline, 0.1% Tween 20) three times at room temperature, followed by (Goatanti-mouse) secondary antibody (ThermoFisher Scientific; 1:1000) for 30 min at 4°C. Densitometric analysis of ApoE was performed (exposure time of 4 minutes with a relative intensity of 2.0, Odyssey imaging system, with application software Version 3.0) followed by an unpaired t-test using GraphPad Prism 5.04 software.
Measurement of Plasma, CSF, and Brain Drug Concentration: Aliquots of plasma (50 μl) were combined with 300 μl of acetonitrile containing 125 μl structurally related internal standard (IS), vortexed, and centrifuged. Supernatant was transferred into a plain polypropylene 96-well plate for sample analysis. Brain tissue samples were homogenized by using a Covaris (Woburn, MA) acoustic homogenizer. Aliquots of 50 μl homogenate were combined with acetonitrile containing a structurally related IS, vortexed, and centrifuged at 1,900 g for 5 minutes. Supernatant was transferred into a 96-well plate for sample analysis. Analytical standards and tissues were measured by liquid chromatography mass spectrometry (Shimadzu Pumps Autosampler Prominence for HPLC and PE Sciex API 4000 for MS, with Analyst 1.6.1 software) using atmospheric-pressure chemical ionization and multiple reaction monitoring in the positive ion mode.
Results
Our aim in this study was to investigate the effects of RXR/LXR agonism on Aβ homeostasis in the CNS of non-transgenic rats using the RXR agonist, bexarotene and the LXR agonist, T0901317. As a positive control, we included a β-secretase inhibitor (AMG8155). Compounds and appropriate vehicle controls were administered to naïve Sprague Dawley rats at doses indicated in Table 1 for either 3 or 7 consecutive days.
Following 3 and 7 days of dosing, animals were evaluated for both compound levels and pharmacodynamic endpoints. APOE levels were quantitated in brain homogenate and CSF by Western blot. Aβ40 levels were quantitated in the same compartments using immunoassay as described in the Materials and methods section. Following 3 and 7 days of dosing, APOE levels were increased in brain and CSF in the T0901317 treated animals compared to vehicle treated animals ( Figure 1 ). Changes in CSF were statistically significant at both 3 (p = 0.0002) and 7 days (p = 0,0007) whereas changes in brain were statistically significant at day 3 (p = 0.030) but did not reach significance at day 7 (p = 0.056). Bexarotene treatment also resulted in a statistically significant increase in CSF APOE levels compared to vehicle treated animals following both 3 (p = 0.019) and 7 days (p = 0.002) of dosing (Figure 2 ). APOE levels in brain following bexarotene treatment trended towards an increase however these changes were not statistically significant. Soluble Aβ40 levels were unchanged in brain and CSF following 3-day ( Figure 3 ) and 7-day ( Figure 4 ) treatment with either bexarotene or T0901317. The positive control BACE inhibitor, AMG8155 effectively reduced Aβ40 levels by 70% and 71% in CSF and by 67% and 69% in brain in the 3-day and 7-day studies respectively (Figure 3 and Figure 4 ). Drug levels of bexarotene and T0901317 were measured in plasma and brain homogenate following 3 and 7 days of dosing (Table 2) . Total levels of both compounds achieved single-digit to low doubledigit μM levels in brain and showed good uptake in brain relative to plasma in both dosing paradigms. 
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Conclusion
In this study we demonstrate that 3-day or 7-day treatment of naïve rats with the LXR agonist, T0901317 or the RXR agonist, bexarotene treatment results in an increase in APOE levels in CSF without observable effects on CSF or brain Aβ40 levels.
Although this study sought to examine the robustness of the hypothesis that RXR/LXR agonism affects soluble Aβ homeostasis, it was not designed to explicitly replicate any one prior study. Differences in findings between labs could very well be a result of a variety of factors related to the methodologies employed, something that has been nicely reviewed for bexarotene previously 14,15 .
Whereas the current report was focused solely on soluble Aβ, we recognize that RXR/LXR agonism may affect AD pathology in other ways (e.g. increased phagocytic clearance of amyloid deposits 16 ). LXR or RXR agonism may also affect cognitive decline in AD patients via non-Aβ-dependent mechanisms not yet fully understood 17 . Moreover, this study exclusively assessed Aβ40 and it remains possible that LXR/RXR agonism may result in Aβ42-specific changes. In most prior studies that have examined changes in soluble Aβ40 and Aβ42 homeostasis, both Aβ species are affected in a similar manner. However, one published report showed that LXR agonism with T0901317 resulted in a selective reduction in Aβ42 in the hippocampus only 11 . Such region-specific changes would not have been detected under our current experimental protocol as whole brain homogenates were analyzed.
Finally, others have shown that the effects of LXR/RXR agonism vary depending on APOE isoform. Treatment of EFAD mice (mice expressing 5XFAD mutations and h-APOE3 or h-APOE4) 18 with bexarotene or bexarotene analog, LG100268, resulted in an increase in APOE4 lipidation and subsequent decrease in soluble, oligomeric Aβ levels 19 . Likewise, in naïve human APOE3 or APOE4 targeted replacement mice, bexarotene treatment increased APOE4 lipidation and decreased E4-associated Aβ42 Following 3 and 7 days of dosing, compound levels were measure in brain homogenate and plasma. Total (t) compound concentrations (μM) are reported in each case. The brain to plasma ratio is also shown (far right-hand column).
and hyperphosphorylated tau accumulation in the hippocampus 20 . The current study was performed in naïve rats expressing endogenous APOE, therefore, human APOE isoform-specific effects would have been beyond the scope of this study.
It remains to be seen how well any of these preclinical findings translate to human clinical trials. Recently, the effect of bexarotene on amyloid burden was assessed in patients with Alzheimer's disease (AD) in a small, proof-of-concept trial 21 . Although the primary outcome of the trial was negative, data suggest that bexarotene resulted in lowering of amyloid burden in APOE4 non-carriers.
We hope that these findings will stimulate future discussion in the Alzheimer's research community on the impact of LXR/RXR agonism on central Aβ homeostasis. 
Data availability
Competing interests
All authors are employees and stockholders of Amgen, Inc.
Grant information
All work was funded by Amgen Inc.
1.
2. In this manuscript, Wang and colleagues report that treatment for 3 and 7 d bexarotene (Bex, an RXR agonist) or T0901317 (TO, an LXR agonist) induce an increase in apoE levels and but have no effect on Aβ40 in the CSF and brain of rats. While the subject matter is timely, the conclusions must be taken with reservations because of three major concerns:
Limited readouts and regions analyzed. It has been previously demonstrated that changes in the levels of Aβ40 and apoE in CSF and brain do not always correlate with efficacy in FAD-Tg mice . Furthermore, it has been shown that an increase of apoE levels by Bex can be beneficial or detrimental depending on the isoform of apoE or the brain region analyzed .
The exclusion of Aβ42. It has been reported that CSF Aβ42 levels, and not Aβ40, are increased in AD patients compared to controls .
Comparison to previous reports. Suon and colleagues (2010) treated rats with LXR agonists TO (at the same dose) or GW3965 and reported an increase in apoE that correlated with an increase in Ab40/42 levels in CSF and a reduction of Aβ40 in brain . Wang and colleagues should reconcile their results with this work specifically and interpret their work in the context of the filed in general.
A minor observation is that in Figure 1A the vehicle is mislabeled as Vehicle 3 (should be Vehicle 4 for TO901317)
Within the AD field, there is an ongoing discussion of the effects of Bex on soluble and deposited Aβ levels in the brain and cognition, with contradictory findings. This is likely due to several confounding factors, including: variance within and across models and inconsistencies in the methods used to characterize and quantify the proteins of interest, particularly soluble Aβ. It is imperative to take these parameters into account when considering the efficacy of RXR or LXR agonists for AD therapeutics. As well, a phase I trial of Bex in AD patients recently concluded . While these results may be of limited significance and were not available for the submission of this manuscript, inclusion of their results in a revision of the Discussion would be helpful. Some controversy has surrounded the report in from Landreth and colleagues showing that Science bexarotene reduces the brain amyloid plaque burden from APP transgenic mice by 50% or more in a matter of days. Several groups of experts attempted to replicate the dramatic Landreth results but the dramatic results were not replicatable. The current paper extends that replication attempt F1000Research story by treating rats with bexarotene and then measuring APP metabolites and apoE in CSF. In agreement with the "second wave" of bexarotene studies, there was no effect of bexarotene on CSF levels of Aβ40 or Aβ42. The one point of agreement of all studies was that bexarotene does indeed modulation CSF levels of apoE. This argues against the development of bexarotene mimetics as Aβ lowering agents for the treatment or prevention of Alzheimer's disease. However, inasmuch as elevating apoE may be beneficial in clinical situations via a non-Aβ-dependent pathway (see http://www.alzforum.org/news/research-news/bexarotene-revisited-improves-mouse-memory-no-effect-plaques ), bexarotene does reproducibly modulate CSF levels of apoE. The discovery of the entity of SNAP (for review, see Jack 2016 ) indicates that about one-third of clinically diagnosed Alzheimer's patients et al., undergo cognitive decline via some as yet unknown non-Aβ-dependent pathway.
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. have reported that they have failed to replicate the ability of bexarotene to clear soluble et al amyloid from the brain. The reason they failed is straightforward. This experiment has been repeated 6 times. This specific issue has been nicely summarized in a paper published by Tesseur and De Strooper , who were authors of one of the 'Comments' on our Science paper. I draw your attention to the (2013) summary table in that paper. The reason Amgen was unable to reproduce our results was that they used the wrong drug formulation. We used the clinically approved formulation of bexarotene (Targretin ), which is a microcrystaline form of the drug. Those laboratories who used this formulation found drug-induced ApoE expression and lowered Abeta levels. Those studies that solubilized the drug prior to administration failed to replicate the published results. The micronization of bexarotene results in very different pharmacokinetic compared to solubilized drug, which was clearly documented by Chen et al.
and in the FDA filings. The micronized form of the drug is slowly absorbed in the gut and (2014 ; Fig 8a) results in sustained plasma (and brain) levels of the drug, whereas the solubilized drug is rapidly absorbed and cleared. The reason this is important is based on the well known mechanisms of nuclear receptor action. Nuclear receptors, like RXR, are ligand-activated transcription factors. Ligand binding to the receptor results in assembly of chromatin remodeling machinery on the enhancers and promoters of its target genes, resulting in epigenetic modifications that open chromatin structure, allowing induction of gene expression. This process takes time, thus there must be sufficiently high drug levels over an extended interval in order for this to be achieved.
The formulation issue was explicitly discussed in the literature and the FDA filing for bexarotene and was detailed on our 'Response' to the ' Comments' in Science ( ). The Amgen scientists Landreth 2013 et al., (and others) clearly did not make an effort to understand and replicate the original study design, nor appreciate the importance of the formulation of the drug as it relates to nuclear receptor action. Although the Amgen study was narrowly focused on ApoE and soluble Abeta 40 and did not examine other aspects of our work, the same considerations apply to other contested outcomes of our study.
The Amgen study employed wild type Sprague-Dawley rats, whereas all other studies with bexarotene used murine models of AD. A study of the LXR agonist TO9001317 in rats that was similar to that of Amgen was published by Merck ( ) and was only partially replicated in the Amgen study Suon , 2010 et al. and was not cited.
Our work on bexarotene has led to clinical examination of its effects in Alzheimer's disease. Cummings and colleagues published the outcome of a phase II study of bexarotene in mild to moderate AD patients last week ( ). While bexarotene treatment did not have a demonstrable effect in Cummings , 2016 et al. individuals possessing an ApoE4 allele, individuals that did not have an ApoE4 gene (representing about 80% of the population) exhibited a robust reduction in brain amyloid with a parallel appearance of Abeta42 in plasma. Thus, a brief 30 day treatment altered two canonical biomarkers of AD in patients with diagnosed disease. These findings are consonant with a recent case report reporting cognitive improvement with bexarotene treatment ( ). I hasten to add that the small study size Pierrot 2015 et al. precludes making any hard conclusions from this trial and they should be interpreted cautiously. However, these preliminary clinical findings support and validate our original report using mouse models of the disease.
I don't think the Amgen study adds anything to what was previously known. The work has a logical flaw that undermines the conclusion that they were unable to repeat our study outcomes, including the use of a TM
